Suppr超能文献

伴间变转化的晚期不可切除分化型甲状腺癌:一例报告及文献复习

Advanced Unresectable Differentiated Thyroid Cancer With Anaplastic Transformation: A Case Report and Review of the Literature.

作者信息

Alzahrani Jehad, Radi Suhaib, Aljabri Abdullah, Alandejani Mohammad

机构信息

Department of Internal Medicine, Division of Endocrinology, Ministry of the National Guard-Health Affairs, Jeddah, SAU.

College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, Jeddah, SAU.

出版信息

Cureus. 2024 Nov 18;16(11):e73956. doi: 10.7759/cureus.73956. eCollection 2024 Nov.

Abstract

Papillary thyroid carcinoma (PTC) is the most common subtype of thyroid cancer (TC). Although surgery and radioactive iodine therapy (RAI) generally yield favorable outcomes, advanced cases with extensive local invasion and metastases pose significant challenges. We report the case of a 65-year-old male with advanced, inoperable PTC characterized by extensive local invasion and distant metastases. A whole-body radioiodine scan revealed no iodine-avid disease. However, following recombinant human thyrotropin (rhTSH) preparation, the patient developed severe compressive symptoms, necessitating glucocorticoid treatment. Lenvatinib monotherapy was initiated, resulting in initial symptom relief. Unfortunately, the disease rapidly progressed due to anaplastic transformation of the PTC, ultimately leading to the patient's death. This report highlights the challenges of managing advanced differentiated TC (DTC) and the risk of aggressive transformation into anaplastic TC (ATC), even with targeted therapy. It underscores the critical need for close monitoring and a multidisciplinary approach. Further research is needed to explore the role of targeted therapies, such as lenvatinib, in altering tumor biology and their long-term effects on disease progression.

摘要

乳头状甲状腺癌(PTC)是甲状腺癌(TC)最常见的亚型。尽管手术和放射性碘治疗(RAI)通常能产生良好的效果,但伴有广泛局部侵犯和转移的晚期病例仍面临重大挑战。我们报告了一例65岁男性晚期不可手术的PTC病例,其特征为广泛的局部侵犯和远处转移。全身放射性碘扫描显示无碘摄取病灶。然而,在使用重组人促甲状腺素(rhTSH)制剂后,患者出现了严重的压迫症状,需要进行糖皮质激素治疗。开始使用乐伐替尼单药治疗,最初症状得到缓解。不幸的是,由于PTC发生间变性转化,疾病迅速进展,最终导致患者死亡。本报告强调了管理晚期分化型甲状腺癌(DTC)的挑战以及即使采用靶向治疗也有向间变性甲状腺癌(ATC)侵袭性转化的风险。它强调了密切监测和多学科方法的迫切需要。需要进一步研究来探索靶向治疗(如乐伐替尼)在改变肿瘤生物学特性及其对疾病进展的长期影响方面的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6311/11655939/6de2e876ce95/cureus-0016-00000073956-i01.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验